| Year |
Title |
Altmetric |
| 2021
|
Cannabidiol (CBD) and cognition in epilepsy.
Epilepsy and Behavior.
124.
2021
|
|
| 2021
|
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy.
Clinical Pharmacology and Therapeutics.
110:1368-1380.
2021
|
|
| 2021
|
Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy.
Epilepsy and Behavior.
122.
2021
|
|
| 2021
|
White matter integrity after cannabidiol administration for treatment resistant epilepsy.
Journal of epilepsy.
172.
2021
|
|
| 2021
|
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Epilepsy and Behavior.
117.
2021
|
|
| 2020
|
Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy.
Epilepsy and Behavior.
112.
2020
|
|
| 2020
|
Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy.
Epilepsy and Behavior.
112.
2020
|
|
| 2020
|
White matter and neurite morphology differ in psychogenic nonepileptic seizures.
Annals of Clinical and Translational Neurology.
7:1973-1984.
2020
|
|
| 2020
|
De Novo Status Epilepticus in patients with COVID-19.
Annals of Clinical and Translational Neurology.
7:1240-1244.
2020
|
|
| 2019
|
Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
Epilepsy and Behavior.
98:201-206.
2019
|
|
| 2019
|
Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy.
Epilepsy and Behavior.
97:105-110.
2019
|
|
| 2019
|
fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy.
Epilepsy and Behavior.
96:114-121.
2019
|
|
| 2019
|
Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol.
Epilepsy and Behavior.
95:131-136.
2019
|
|
| 2019
|
Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy.
Epilepsy and Behavior.
95:10-17.
2019
|
|
| 2019
|
A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy
2019
|
|
| 2019
|
Memory response and neuroimaging correlates of a novel cognitive rehabilitation program for memory problems in epilepsy: A pilot study.
Restorative Neurology and Neuroscience.
37:457-468.
2019
|
|
| 2018
|
Cannabis for the Treatment of Epilepsy: an Update.
Current Neurology and Neuroscience Reports.
18.
2018
|
|
| 2018
|
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
Epilepsy and Behavior.
87:131-136.
2018
|
|
| 2018
|
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study
Pongkiat Kankirawatana, Dr Rani Singh, Professor David G Standaert, Dr Yuliang Liu, Dr Leon Dure, Dr Jennifer DeWollfe, Professor Gary Cutter, Dr Tyler Gaston, Dr Ashley Thomas, Professor E. Martina Bebin, Dr. Lawrence Ver Hoef.
Epilepsy and Behavior.
(in press).
2018
|
|
| 2017
|
Interactions between cannabidiol and commonly used antiepileptic drugs.
Epilepsia.
58:1586-1592.
2017
|
|
| 2017
|
Pharmacology of cannabinoids in the treatment of epilepsy.
Epilepsy and Behavior.
70:313-318.
2017
|
|
| 2016
|
Which patients with epilepsy are at risk for psychogenic nonepileptic seizures (PNES)? A multicenter case–control study.
Epilepsy and Behavior.
61:180-184.
2016
|
|
| 2016
|
White matter abnormalities in patients with treatment-resistant genetic generalized epilepsies
2016
|
|
| 2015
|
White matter diffusion abnormalities in patients with psychogenic non-epileptic seizures.
Brain Research.
1620:169-176.
2015
|
|
